General Catalyst Group Management’s Teladoc Health TDOC Stock Holding History

General Catalyst Group Management’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-581,347	Closed	-$19.3M	–	16
2022 Q2	$19.3M	Hold	581,347	–	–	1.72%	12
2022 Q1	$41.9M	Hold	581,347	–	–	2.38%	8
2021 Q4	$53.4M	Sell	581,347 -2,102,791	-78%	-$251M	2.03%	9
2021 Q3	$340M	Sell	2,684,138 -2,684,138	-50%	-$391M	17.32%	2
2021 Q2	$893M	Sell	5,368,276 -1,342,069	-20%	-$217M	38.61%	1
2021 Q1	$1.22B	Sell	6,710,345 -1,342,068	-17%	-$311M	47.13%	1
2020 Q4	$1.61B	Buy	+8,052,413	New	+$1.64B	55.05%	1

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

General Catalyst Group Management's TDOC Position: Q3 2022 in Review

General Catalyst Group Management sold out of Teladoc Health (TDOC) in Q3 2022, closing a stake of 581,347 shares — an estimated $19.3M sold.

General Catalyst Group Management first reported a position in TDOC in Q4 2020 and held it in 7 quarters. The position peaked at $1.61B in Q4 2020. 482 funds tracked by Wall St. Rank hold TDOC as of Q3 2022.

General Catalyst Group Management reported no remaining Teladoc Health position as of Q3 2022 after selling out during the quarter.
General Catalyst Group Management sold 581,347 Teladoc Health shares in Q3 2022, an estimated $19.3M.
General Catalyst Group Management first reported a position in Teladoc Health in Q4 2020 and held it in 7 quarters.
General Catalyst Group Management's Teladoc Health position peaked at $1.61B in Q4 2020.
482 funds tracked by Wall St. Rank held Teladoc Health as of Q3 2022.

Based on General Catalyst Group Management's 13F filing for Q3 2022, filed 9 Nov 2022.